T. Rowe Price Investment Management, Inc. Hille Vax, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Hille Vax, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,481,222 shares of HLVX stock, worth $6.13 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,481,222
Previous 3,061,704
13.7%
Holding current value
$6.13 Million
Previous $50.9 Million
1.14%
% of portfolio
0.03%
Previous 0.03%
Shares
8 transactions
Others Institutions Holding HLVX
# of Institutions
93Shares Held
40.5MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$18.7 Million9.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4MShares$7.05 Million1.22% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$3.68 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.99MShares$3.5 Million0.01% of portfolio
-
Abingworth LLP London, X01.84MShares$3.24 Million10.2% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $58.8M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.